Skip to content
Review Open access

Nanomaterials Reshaping Tumor Metabolism: A New Frontier to Overcome T Cell Exhaustion

Oct 2026 · International Journal of Nanomedicine · Vol 21, pp. 1-29 · 0 citations · 200 references
Medicine

TL;DR

This review identifies the key gaps that currently limit clinical translation: the absence of subset-level evaluation distinguishing reversible progenitor-like exhausted T cells from terminally exhausted cells, the lack of epigenetic endpoints such as histone lactylation, off-target metabolic suppression of T cells themselves, and the manufacturing and safety hurdles of clinical-grade nanomaterials.

Abstract

Abstract Adoptive antitumor immunity ultimately fails because metabolically hostile tumor microenvironments (TME) drive T cells into a dysfunctional exhausted state that current checkpoint blockade only partially reverses. Crucially, the principal metabolic stresses — accumulation of lactate, lipids and adenosine, deprivation of glucose and amino acids, and hypoxia — do not act in isolation but form a densely cross-regulated network that progressively reinforces T cell exhaustion. This review synthesizes how each barrier arises and how they amplify one another, then maps nanomaterial-based countermeasures onto this network: catalytic nanomaterials that degrade lactate and adenosine, lipid-modulating and mitochondria-targeted formulations, amino-acid replenishment systems, and hypoxia-relieving designs that pair metabolic correction with checkpoint inhibition or photodynamic therapy. Particular attention is given to the design principles — tissue targeting, stimuli-responsive release and rational combination — that determine whether metabolic reprogramming yields durable restoration of T cell function rather than transient phenotypic rescue. Emerging preclinical evidence indicates that nanomaterial-mediated metabolic remodeling can convert the immunosuppressive TME into an immune-supportive niche and recover effector function of exhausted T cells. We further identify the key gaps that currently limit clinical translation: the absence of subset-level evaluation distinguishing reversible progenitor-like exhausted T cells from terminally exhausted cells, the lack of epigenetic endpoints such as histone lactylation, off-target metabolic suppression of T cells themselves, and the manufacturing and safety hurdles of clinical-grade nanomaterials. Resolving these issues would establish metabolic reprogramming as a credible frontier for next-generation cancer immunotherapy.

Read PDF

Similar papers

Open access Oct 2026

Dual Metabolic Inhibition Via Vanadium-NO Synergistic Nanoplatform Potentiates Cancer Immunotherapy.

Immunotherapy has emerged as a pivotal strategy in cancer treatment. However, tumor metabolic reprogramming not only promotes cancer cell survival but also fosters an immunosuppressive tumor microenvironment (TME), thereby hindering immune activation. To address these challenges, we developed a novel multifunctional hy...

Rui-Zhi Tian, Ze Song, Zheng-Yi Lan et al. · 0 citations
Review Open access Oct 2026

Engineering clinically actionable nanomedicine for cancer immunometabolic ecosystem reprogramming

Summary Traditional metabolic inhibitors have limited clinical efficacy, with issues such as narrow window periods, and compensatory effects. These barriers indicate that effective metabolic therapy requires spatially restricted, temporally coordinated, cell-context-aware, and clinically stratifiable intervention. This...

Yu-Hong Gao, Xiu-Lin Dong, Si-Jia Hua et al. · 0 citations
Review Oct 2026

Emerging nanomedicine upshot: Reprogramming cellular dormancy for tissue regeneration.

Trends in regenerative medicine are transforming the field by moving beyond simple repair to actively reprogram cellular and tissue environments. This review explores new approaches that integrate nanotechnology, metabolic regulation, and immune engineering to improve the regeneration of tissues that are otherwise diff...

Tiya Rawat, Nida Irfan Pathan, Devyani Sengar et al. · 0 citations
Review Open access Sep 2026

Metabolic Barriers to Cancer Immunotherapy: Multiscale Mechanisms from Organelle Dysfunction to Organ-Specific Constraints

Immune checkpoint blockade (ICB) has reshaped cancer therapy, yet primary resistance and acquired relapse remain common despite therapeutic targeting of inhibitory receptor pathways. This limitation suggests that checkpoint release may remain insufficient when antitumor lymphocytes lack the metabolic, organelle-level,...

Zi-Chen Gui, Xiao-Yi Yuan, Xiao-Ping Chen et al. · 0 citations
Review Open access Sep 2026

Targeting metabolic reprogramming in persister cancer cells: Emerging insights and therapeutic opportunities.

ABSTRACT Persister cancer cells (PCCs) constitute a transient tumor subpopulation that survives anticancer therapy by entering a drug-tolerant state, characterized by enhanced stress resilience and profound metabolic adaptation. Unlike genetically resistant clones, PCCs rely on reversible metabolic adaptations centrall...

Si-Qi Li, Chun-Xiu Xiao, Jinxing Huang et al. · 0 citations
Conference Open access Oct 2026

T Cell Dysfunction in the Necrotic Tumor Microenvironment: Ions, Metabolism, and Immunotherapy

T cells are basically essential for all types of antitumor immunity, however, their function can become impaired within the tumor microenvironment (TME). Tumor necrosis helps promote TME conditions where factors such as ionic imbalances, hypoxia, and nutrient deprivation may end up driving T cell-dysfunction. This revi...

Spandan Pradhan · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.